Price T Rowe Associates Inc. MD Purchases 612,154 Shares of Danaher Corporation $DHR

Price T Rowe Associates Inc. MD increased its position in shares of Danaher Corporation (NYSE:DHR) by 3.2% in the first quarter, Holdings Channel reports. The institutional investor owned 19,592,211 shares of the conglomerate’s stock after buying an additional 612,154 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Danaher were worth $4,016,404,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. GHP Investment Advisors Inc. raised its holdings in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in Danaher during the fourth quarter worth $27,000. Sierra Ocean LLC grew its position in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher in the first quarter valued at about $31,000. Finally, Dunhill Financial LLC raised its stake in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price for the company in a research note on Friday, July 11th. UBS Group dropped their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. HSBC cut their target price on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Leerink Partners upped their price target on shares of Danaher from $225.00 to $230.00 and gave the company an “outperform” rating in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Stock Down 0.4%

Shares of NYSE DHR opened at $211.2470 on Thursday. The stock’s fifty day moving average is $200.46 and its 200 day moving average is $199.62. The stock has a market capitalization of $151.26 billion, a P/E ratio of 44.95, a PEG ratio of 2.96 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.